Skip Navigation LinksHome > December 2013 - Volume 8 - Issue 12 > Overexpression of EPH Receptor B2 in Malignant Mesothelioma...
Journal of Thoracic Oncology:
doi: 10.1097/01.JTO.0000437389.32117.3e

Overexpression of EPH Receptor B2 in Malignant Mesothelioma Correlates with Oncogenic Behavior: Erratum

Free Access

We would like to point out a methodologic error regarding peptide sc-1763P from Santa Cruz which we used for part of our EphB2 functional assays. SC-1763P is, in reality, not an EphB2 blocking peptide, and in fact is sold as a control to block the anti-EphB2 antibody sc-1763P. Hence, based on the information available on the sc-1763P peptide the effects we observed in the experiments shown in Fig. 5 are nonspecific effects and should not be attributed to inhibiting EphB2. Our shRNA data in the manuscript, however, will stand as proof of principle for the demonstration of the functional events associated with EphB2 in mesothelioma. Our gratitude to Dr. Elaine Pasquale, Professor at the Sanford-Burnham Medical Research Institute in La Jolla and an internationally renowned ephrin expert, for pointing out this error. Harvey I. Pass, MD Chandra Goparaju, PhD NYU Langone Medical Center New York, NY

Back to Top | Article Outline


Goparaju C, Donington JS, Hsu T, Harrington R, Hirsch N, Pass HI. Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior. J Thorac Oncol. 2013;8:1203–1211

Copyright © 2013 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.


Article Tools


Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.